Related Experiment Video

Updated: Apr 7, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.5K

Dual-Modality Liver-Directed Therapy for Primary Liver Cancer

Charles R Thomas

    JAMA Oncology
    |July 17, 2015
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
    09:49

    Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

    Published on: December 2, 2013

    10.9K
    Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
    08:54

    Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

    Published on: May 8, 2018

    15.2K

    Related Experiment Videos

    Last Updated: Apr 7, 2026

    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
    09:11

    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

    Published on: May 24, 2024

    1.5K
    Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
    09:49

    Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

    Published on: December 2, 2013

    10.9K
    Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
    08:54

    Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

    Published on: May 8, 2018

    15.2K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    9.1K
    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.1K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    6.4K
    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    6.4K

    Articles linked to this work by shared authors, journal, and citation graph.

    Phase Ib Study to Assess the Safety of Neoadjuvant Trifluridine/Tipiracil With Concurrent Radiation in Resectable Stage II/III Rectal Cancer: The FIERCE Study.

    Clinical colorectal cancer·2026

    Jurisdiction firearm prevalence and increasing suicide in United States adolescents and young adults.

    Journal of the National Medical Association·2025

    Dosimetric evaluations using cycle-consistent generative adversarial network synthetic CT for MR-guided adaptive radiation therapy.

    Frontiers in oncology·2025

    National Institutes of Health Funding to Support Radiation Oncology Research: A Comparative Trend Analysis Over a Decade, 2011-2021.

    Advances in radiation oncology·2025

    Postprogression therapy and confounding for the estimated treatment effect on overall survival in phase III oncology trials.

    BMJ oncology·2025

    Off-Protocol Radiation Therapy in Phase 3 Metastatic Solid Tumor Trials.

    International journal of radiation oncology, biology, physics·2024

    Federal and Industry Sponsorship in US Cancer Clinical Trials.

    JAMA oncology·2026

    Trends in Meningioma Incidence, Treatment, and Imaging Surveillance.

    JAMA oncology·2026

    Racial and Ethnic Disparities in US Colorectal Cancer Mortality by County, Sex, and Age.

    JAMA oncology·2026

    Metabolic Dysfunction After Initiation of Androgen Receptor Pathway Inhibitors in Prostate Cancer.

    JAMA oncology·2026

    Tissue-Free vs Tumor-Informed ctDNA Assays for Molecular Residual Disease Detection in Early Triple Negative Breast Cancer.

    JAMA oncology·2026

    Electronic Patient-Reported Outcome Monitoring With Alert-Based Interventions in Metastatic Breast Cancer: A Randomized Clinical Trial.

    JAMA oncology·2026

    Clinical management of adverse events in patients with advanced HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine.

    The oncologist·2026

    Treatment Initiation of Definitive Radiotherapy in Patients With Locally Advanced Head and Neck Cancer.

    Cancer control : journal of the Moffitt Cancer Center·2026

    [Retracted] Restoration of the tumor‑suppressor function to mutant p53 by Ganoderma lucidum polysaccharides in colorectal cancer cells.

    Oncology reports·2026

    Octreotide as Adjunctive Therapy for Catecholamine-Secreting Pheochromocytoma and Paraganglioma.

    The Journal of clinical endocrinology and metabolism·2026

    Zanubrutinib versus fludarabine, cyclophosphamide and rituximab in fit, treatment-naïve patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison.

    Journal of comparative effectiveness research·2026

    Prognosis of Extramedullary Disease in Chinese Newly Diagnosed Multiple Myeloma Patients Treated With Novel Agents-Based Induction Therapy.

    Cancer medicine·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us